Aug 24, 2016 9:05am EDT SCYNEXIS, Inc. Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections
Aug 08, 2016 9:05am EDT SCYNEXIS, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Update
Aug 01, 2016 8:00am EDT SCYNEXIS Announces Interim Results from Phase 2 Study of Oral SCY-078 in Patients with Invasive Candidiasis
Jul 13, 2016 8:30am EDT SCYNEXIS, Inc. Announces Sale of Cyclophilin Inhibitor Assets to Cypralis Limited
Jul 06, 2016 9:05am EDT SCYNEXIS, Inc. to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
Jun 21, 2016 9:15am EDT SCYNEXIS Announces Pricing of $22.5 Million Public Offering of Common Stock and Warrants
Jun 20, 2016 8:00am EDT SCYNEXIS Inc. Presents New Clinical and Non-Clinical Data Confirming the Potential of SCY-078 as a Novel Treatment for Life-threatening Fungal Infections
Jun 10, 2016 9:05am EDT SCYNEXIS to Present Data from Lead Antifungal Drug Candidate SCY-078 at ASM Microbe 2016
